[
  {
    "ts": null,
    "headline": "Dow Jones Futures: Risk-Off Shift For Stock Market? Google, AMD, Amazon, Palantir On Tap",
    "summary": "The stock market tested key levels to end the week while gold and silver dived in a risk-off shift. Google, AMD, Eli Lilly, Amazon and Palantir headline another big earnings week.",
    "url": "https://finnhub.io/api/news?id=0c1bb1a7b7b6d08290ed36e0750a6175f5b7672a5937016ca32672ee76e8430b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769809269,
      "headline": "Dow Jones Futures: Risk-Off Shift For Stock Market? Google, AMD, Amazon, Palantir On Tap",
      "id": 138310166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market tested key levels to end the week while gold and silver dived in a risk-off shift. Google, AMD, Eli Lilly, Amazon and Palantir headline another big earnings week.",
      "url": "https://finnhub.io/api/news?id=0c1bb1a7b7b6d08290ed36e0750a6175f5b7672a5937016ca32672ee76e8430b"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
    "url": "https://finnhub.io/api/news?id=81af2fa2cfff61740368b9cade42937cd03941c2ea209e5b4e2b2b7957320218",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769806256,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 138310211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
      "url": "https://finnhub.io/api/news?id=81af2fa2cfff61740368b9cade42937cd03941c2ea209e5b4e2b2b7957320218"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Plans $3.5 Billion Facility in Pennsylvania to Develop New Weight-Loss Drugs",
    "summary": "Eli Lilly (LLY) said Friday it intends to invest more than $3.5 billion in a new facility in Pennsyl",
    "url": "https://finnhub.io/api/news?id=0af84ab8dd67c103ba9e5fd96ca2b9b2596ad878a7bb0e929e461dd657e654ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769804212,
      "headline": "Eli Lilly Plans $3.5 Billion Facility in Pennsylvania to Develop New Weight-Loss Drugs",
      "id": 138310212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Friday it intends to invest more than $3.5 billion in a new facility in Pennsyl",
      "url": "https://finnhub.io/api/news?id=0af84ab8dd67c103ba9e5fd96ca2b9b2596ad878a7bb0e929e461dd657e654ed"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Fails to Win EU Approval for Mounjaro Heart Failure Label",
    "summary": "EMA declines new indication but will add supporting data to drug label.",
    "url": "https://finnhub.io/api/news?id=8f4be2aae85f12626bd606c94a3fc03e7936b2cec99088564dcbb7f7b5c8877c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769801755,
      "headline": "Eli Lilly Fails to Win EU Approval for Mounjaro Heart Failure Label",
      "id": 138310213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "EMA declines new indication but will add supporting data to drug label.",
      "url": "https://finnhub.io/api/news?id=8f4be2aae85f12626bd606c94a3fc03e7936b2cec99088564dcbb7f7b5c8877c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Jumps Ahead as Wegovy Pill Takes Off",
    "summary": "Oral obesity drug draws early demand",
    "url": "https://finnhub.io/api/news?id=e475d70f61727535aea810a6951c517033168e69b369974200ebfe60f8bc9463",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769799560,
      "headline": "Novo Jumps Ahead as Wegovy Pill Takes Off",
      "id": 138308822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Oral obesity drug draws early demand",
      "url": "https://finnhub.io/api/news?id=e475d70f61727535aea810a6951c517033168e69b369974200ebfe60f8bc9463"
    }
  },
  {
    "ts": null,
    "headline": "Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion",
    "summary": "Drugmaker Eli Lilly and Co. said Friday that it will build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments.  Indianapolis-based Eli Lilly, maker of weight-loss treatment Zepbound and diabetes drug Mounjaro, is in the midst of a broader domestic expansion that includes new plants it has announced in Texas, Virginia and Alabama.  The company said the new plant in Fogelsville, just outside Allentown, will make injectable drugs and devices, including producing weight-loss drug retatrutide, a once-a-week injectable drug that is still being studied and not available for public use.",
    "url": "https://finnhub.io/api/news?id=0e18fbaa2cbe24003799a2b6cf8a2bec727b44099cb22637984d41ca14b27ca1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769793027,
      "headline": "Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion",
      "id": 138307272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmaker Eli Lilly and Co. said Friday that it will build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments.  Indianapolis-based Eli Lilly, maker of weight-loss treatment Zepbound and diabetes drug Mounjaro, is in the midst of a broader domestic expansion that includes new plants it has announced in Texas, Virginia and Alabama.  The company said the new plant in Fogelsville, just outside Allentown, will make injectable drugs and devices, including producing weight-loss drug retatrutide, a once-a-week injectable drug that is still being studied and not available for public use.",
      "url": "https://finnhub.io/api/news?id=0e18fbaa2cbe24003799a2b6cf8a2bec727b44099cb22637984d41ca14b27ca1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push",
    "summary": "WASHINGTON, Jan 30 (Reuters) - Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and",
    "url": "https://finnhub.io/api/news?id=f4cc3bed64f6c4a0b48fb92cbb60541c7a7beff7f75cbc7fbb6460fdb65cd68c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769789304,
      "headline": "Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push",
      "id": 138307273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "WASHINGTON, Jan 30 (Reuters) - Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and",
      "url": "https://finnhub.io/api/news?id=f4cc3bed64f6c4a0b48fb92cbb60541c7a7beff7f75cbc7fbb6460fdb65cd68c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will serve as Lilly's newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the fourth new U.S. manufacturing site Lilly has announced since February",
    "url": "https://finnhub.io/api/news?id=5eedbddf0cc8953e6f68b55a78771223ee91df2294585a1b51f7ca5f06f97ce5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769788800,
      "headline": "Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility",
      "id": 138307275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will serve as Lilly's newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the fourth new U.S. manufacturing site Lilly has announced since February",
      "url": "https://finnhub.io/api/news?id=5eedbddf0cc8953e6f68b55a78771223ee91df2294585a1b51f7ca5f06f97ce5"
    }
  },
  {
    "ts": null,
    "headline": "Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory",
    "summary": "The region is attempting to build on its status as a manufacturing hub with bigger investments and more tax perks for corporate investors.",
    "url": "https://finnhub.io/api/news?id=8cf73bd4be672304e484ffe016a378c1e7f2bae6031eb49930d17462b205c292",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769788800,
      "headline": "Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory",
      "id": 138307274,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The region is attempting to build on its status as a manufacturing hub with bigger investments and more tax perks for corporate investors.",
      "url": "https://finnhub.io/api/news?id=8cf73bd4be672304e484ffe016a378c1e7f2bae6031eb49930d17462b205c292"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Jump 14% as Wegovy Pill Launch Lifts Sentiment",
    "summary": "The stock rebounds after its worst year as Novo beats Eli Lilly to market with an oral obesity drug.",
    "url": "https://finnhub.io/api/news?id=c00fd205322d2c0d808a4575f0e85b2c057af86eb1819ff75ad29878b3950cb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769788664,
      "headline": "Novo Nordisk Shares Jump 14% as Wegovy Pill Launch Lifts Sentiment",
      "id": 138307276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock rebounds after its worst year as Novo beats Eli Lilly to market with an oral obesity drug.",
      "url": "https://finnhub.io/api/news?id=c00fd205322d2c0d808a4575f0e85b2c057af86eb1819ff75ad29878b3950cb3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Fails to Get EU Regulator's Approval for Mounjaro Label Expansion",
    "summary": "Eli Lilly (LLY) failed to get a recommendation from the European Medicines Agency for its applicatio",
    "url": "https://finnhub.io/api/news?id=ac84b5a6a577de9310b15d60c6b2a048bd0f2f9fa93fae43fb39a8b31ad128e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769786328,
      "headline": "Eli Lilly Fails to Get EU Regulator's Approval for Mounjaro Label Expansion",
      "id": 138307277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) failed to get a recommendation from the European Medicines Agency for its applicatio",
      "url": "https://finnhub.io/api/news?id=ac84b5a6a577de9310b15d60c6b2a048bd0f2f9fa93fae43fb39a8b31ad128e1"
    }
  },
  {
    "ts": null,
    "headline": "FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock?",
    "summary": "The target action date for orforglipron is now April 10.",
    "url": "https://finnhub.io/api/news?id=8913b49ad2976920fbed0f943a9e4f5030ae386c6733679d4af427a91bc8a294",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769785980,
      "headline": "FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock?",
      "id": 138306131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The target action date for orforglipron is now April 10.",
      "url": "https://finnhub.io/api/news?id=8913b49ad2976920fbed0f943a9e4f5030ae386c6733679d4af427a91bc8a294"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?",
    "summary": "NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.",
    "url": "https://finnhub.io/api/news?id=e0a4acce399d804038fa82cf55edd0457c5f07319f9222ff9069c8134fb5e6d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769785560,
      "headline": "Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?",
      "id": 138307278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.",
      "url": "https://finnhub.io/api/news?id=e0a4acce399d804038fa82cf55edd0457c5f07319f9222ff9069c8134fb5e6d8"
    }
  },
  {
    "ts": null,
    "headline": "Novo's Wegovy pill surpasses 26,000 prescriptions in second full week",
    "summary": "STORY: Novo Nordisk's Wegovy pill hit over 26,000 U.S. prescriptions in the second full week after its launch.That's according to data shared on Friday (January 30).Investors are closely watching prescription data to see if the Danish drugmaker can press its first-mover advantage against rival Eli Lilly.They're battling it out in a competitive weight-loss market.Despite oral obesity treatments offering patients greater convenience, injectable medications are still expected to dominate for years to come.Barclays analysts said the Wegovy pill was prescribed over 26,100 times for the week ended January 23rd.They added it suggests the launch of the oral drug is very strong.Market watchers have said the prescription data signals strong early uptake and tracks ahead of launches of other GLP-1s.That's as drugmakers shift towards the cash-paying consumer market.",
    "url": "https://finnhub.io/api/news?id=e7ccc0a2016803fc5cdf81cff7b5d618fcd9c7bc092616a36bb58869f95878d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769784946,
      "headline": "Novo's Wegovy pill surpasses 26,000 prescriptions in second full week",
      "id": 138306132,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk's Wegovy pill hit over 26,000 U.S. prescriptions in the second full week after its launch.That's according to data shared on Friday (January 30).Investors are closely watching prescription data to see if the Danish drugmaker can press its first-mover advantage against rival Eli Lilly.They're battling it out in a competitive weight-loss market.Despite oral obesity treatments offering patients greater convenience, injectable medications are still expected to dominate for years to come.Barclays analysts said the Wegovy pill was prescribed over 26,100 times for the week ended January 23rd.They added it suggests the launch of the oral drug is very strong.Market watchers have said the prescription data signals strong early uptake and tracks ahead of launches of other GLP-1s.That's as drugmakers shift towards the cash-paying consumer market.",
      "url": "https://finnhub.io/api/news?id=e7ccc0a2016803fc5cdf81cff7b5d618fcd9c7bc092616a36bb58869f95878d4"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Alphabet, Amazon, Palantir, Novo Nordisk and Shell",
    "summary": "Earnings preview of key companies reporting next week and what to look out for",
    "url": "https://finnhub.io/api/news?id=8c9233f8c36ce5a1d990eaced9084a4f31dee220086d025eb31dcec391f9feee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769783255,
      "headline": "Stocks to watch next week: Alphabet, Amazon, Palantir, Novo Nordisk and Shell",
      "id": 138306047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting next week and what to look out for",
      "url": "https://finnhub.io/api/news?id=8c9233f8c36ce5a1d990eaced9084a4f31dee220086d025eb31dcec391f9feee"
    }
  },
  {
    "ts": null,
    "headline": "Unveiling Lilly (LLY) Q4 Outlook: Wall Street Estimates for Key Metrics",
    "summary": "Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://finnhub.io/api/news?id=4edee6907d14f5d264bfe9860c29f359aa937c3fc546aee9404a77c86196190a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769782509,
      "headline": "Unveiling Lilly (LLY) Q4 Outlook: Wall Street Estimates for Key Metrics",
      "id": 138307279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
      "url": "https://finnhub.io/api/news?id=4edee6907d14f5d264bfe9860c29f359aa937c3fc546aee9404a77c86196190a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Beyond GLP 1 With New Deals And Cancer Win",
    "summary": "Eli Lilly (NYSE:LLY) announced a collaboration with Repertoire Immune Medicines to develop next generation autoimmune therapies. The company also entered a collaboration with Seamless Therapeutics focused on programmable gene editing treatments for hearing loss. Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan, an ovarian cancer drug in late stage development. Eli Lilly, trading at around $1,024.14, has been a major large cap healthcare name, with a 25.3% return...",
    "url": "https://finnhub.io/api/news?id=fc5a3cd38b417e4b6c7dfbaae5820e32e8b397b9062adef62cd564ee1360d493",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769782322,
      "headline": "Eli Lilly Expands Beyond GLP 1 With New Deals And Cancer Win",
      "id": 138306134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) announced a collaboration with Repertoire Immune Medicines to develop next generation autoimmune therapies. The company also entered a collaboration with Seamless Therapeutics focused on programmable gene editing treatments for hearing loss. Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan, an ovarian cancer drug in late stage development. Eli Lilly, trading at around $1,024.14, has been a major large cap healthcare name, with a 25.3% return...",
      "url": "https://finnhub.io/api/news?id=fc5a3cd38b417e4b6c7dfbaae5820e32e8b397b9062adef62cd564ee1360d493"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Roundup: Big Name Earnings",
    "summary": "Large cap tech earnings. Health insurance stocks drop. Good news in travel and leisure. Interesting new Fed Chair.",
    "url": "https://finnhub.io/api/news?id=760a48a16e5d38ec85c69d461827e030e5d63090e3f0b10f0e85d38541fb28f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769781000,
      "headline": "Wall Street Roundup: Big Name Earnings",
      "id": 138308182,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252783461/image_2252783461.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Large cap tech earnings. Health insurance stocks drop. Good news in travel and leisure. Interesting new Fed Chair.",
      "url": "https://finnhub.io/api/news?id=760a48a16e5d38ec85c69d461827e030e5d63090e3f0b10f0e85d38541fb28f9"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Eli Lilly Before Feb. 4?",
    "summary": "Is there another beat-and-raise in the pharmaceutical giant's near future?",
    "url": "https://finnhub.io/api/news?id=0e761d1889ae1026d355325198610ec1e0da5bc3cfb4c9fc013ee6b90ea843cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769776500,
      "headline": "Should You Buy Eli Lilly Before Feb. 4?",
      "id": 138305297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Is there another beat-and-raise in the pharmaceutical giant's near future?",
      "url": "https://finnhub.io/api/news?id=0e761d1889ae1026d355325198610ec1e0da5bc3cfb4c9fc013ee6b90ea843cd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections",
    "summary": "The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.",
    "url": "https://finnhub.io/api/news?id=9def09c9e2d144b9261c15a406966e5beed876bcd744cc3601d4c0c2c7ff39c2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769770920,
      "headline": "Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections",
      "id": 138306911,
      "image": "https://image.cnbcfm.com/api/v1/image/108203000-17586586822025-09-23t201605z_1719661872_rc2oxga1dwo0_rtrmadp_0_usa-lilly.jpeg?v=1769792784&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial. ",
      "url": "https://finnhub.io/api/news?id=9def09c9e2d144b9261c15a406966e5beed876bcd744cc3601d4c0c2c7ff39c2"
    }
  },
  {
    "ts": null,
    "headline": "Repertoire and Lilly join hands on autoimmune disease therapies",
    "summary": "The agreement grants Repertoire an upfront payment of $85m, with the possibility of up to $1.84bn in additional milestone payments.",
    "url": "https://finnhub.io/api/news?id=11e0d092ad948f0c034681a5b39f9049cd7a43a0d7d991df294aa861d90f7990",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769770437,
      "headline": "Repertoire and Lilly join hands on autoimmune disease therapies",
      "id": 138304569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agreement grants Repertoire an upfront payment of $85m, with the possibility of up to $1.84bn in additional milestone payments.",
      "url": "https://finnhub.io/api/news?id=11e0d092ad948f0c034681a5b39f9049cd7a43a0d7d991df294aa861d90f7990"
    }
  },
  {
    "ts": null,
    "headline": "How Big Pharma is navigating a $300 billion patent cliff",
    "summary": "Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses.",
    "url": "https://finnhub.io/api/news?id=7d91a831517f4f71b90aac9882298a5796b320a690d2e8febe8a55ec5f02581d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769760000,
      "headline": "How Big Pharma is navigating a $300 billion patent cliff",
      "id": 138305298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses.",
      "url": "https://finnhub.io/api/news?id=7d91a831517f4f71b90aac9882298a5796b320a690d2e8febe8a55ec5f02581d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Obesity Pill Spurs Rally After Stock’s Worst Ever Year",
    "summary": "Novo started selling its Wegovy pill a few weeks ago, beating rival Eli Lilly & Co. to market and boosting sentiment after a string of bad news pummeled the shares last year.  “2026 will be a transition year,” said Robert Hannaford, deputy portfolio manager of the Evenlode Global Income fund, adding that the pill launch seems to be going well.  Analysts at Goldman Sachs Group Inc. agree.",
    "url": "https://finnhub.io/api/news?id=273cf6fe91676018a036b2fdc44a2a3da67ebfe37174d5b5931bc1ef3f1201ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769759596,
      "headline": "Novo Obesity Pill Spurs Rally After Stock’s Worst Ever Year",
      "id": 138304570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo started selling its Wegovy pill a few weeks ago, beating rival Eli Lilly & Co. to market and boosting sentiment after a string of bad news pummeled the shares last year.  “2026 will be a transition year,” said Robert Hannaford, deputy portfolio manager of the Evenlode Global Income fund, adding that the pill launch seems to be going well.  Analysts at Goldman Sachs Group Inc. agree.",
      "url": "https://finnhub.io/api/news?id=273cf6fe91676018a036b2fdc44a2a3da67ebfe37174d5b5931bc1ef3f1201ac"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China’s CSPC",
    "summary": "The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.",
    "url": "https://finnhub.io/api/news?id=f0af40e3cc3f1ab2971987129d9ea8270164e65e0910fad15a0808499dc3c0bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769759460,
      "headline": "AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China’s CSPC",
      "id": 138304027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.",
      "url": "https://finnhub.io/api/news?id=f0af40e3cc3f1ab2971987129d9ea8270164e65e0910fad15a0808499dc3c0bf"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC",
    "summary": "The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.",
    "url": "https://finnhub.io/api/news?id=f8fb0b11653ea8824dffa9b98e7788ce7ad9a68808d4b17f26c5466f695a0152",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769758560,
      "headline": "AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC",
      "id": 138305299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.",
      "url": "https://finnhub.io/api/news?id=f8fb0b11653ea8824dffa9b98e7788ce7ad9a68808d4b17f26c5466f695a0152"
    }
  },
  {
    "ts": null,
    "headline": "Why Dividend Stocks Are Essential For What Comes Next",
    "summary": "High-quality dividend stocks like OKE, PFE, and CAG gain as low rates and OKE's 5.6% yield drive upside. Find out why SCHD and value plays offer 2026 growth.",
    "url": "https://finnhub.io/api/news?id=d14019912383ddf146a3820879a00cef930e62688d21dfbb1a03b4cbc3d6c786",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769758200,
      "headline": "Why Dividend Stocks Are Essential For What Comes Next",
      "id": 138304852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1050058124/image_1050058124.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "High-quality dividend stocks like OKE, PFE, and CAG gain as low rates and OKE's 5.6% yield drive upside. Find out why SCHD and value plays offer 2026 growth.",
      "url": "https://finnhub.io/api/news?id=d14019912383ddf146a3820879a00cef930e62688d21dfbb1a03b4cbc3d6c786"
    }
  }
]